CoChat

Update on Surveillance in Von Hippel–Lindau Disease

Rednam, Surya P., Becktell, Kerri D., Villani, Anita, Brodeur, Garrett M., States, Lisa J., Doria, Andrea S., Kamihara, Junne, Schneider, Kami Wolfe, Voss, Stephan D., Widjaja, Elysa, Zelley, Kristin, Nakano, Yoshiko, Pajtler, Kristian W., Achatz, Maria Isabel, Malkin, David, Diller, Lisa R., Gallinger, Bailey, Tamura, Chieko, Wasserman, Jonathan D. · 2025 · Clinical Cancer Research
Cited by 17

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Von Hippel–Lindau disease (VHL) is a genetic condition characterized by a high lifetime risk for tumors and cysts throughout the body, including the central nervous system, visual–auditory systems, and intra-abdominal organs. This neoplasia leads to significant morbidity and potential mortality in affected individuals. Tumor surveillance enables early intervention and leads to improved clinical outcomes. Since the 2017 publication of VHL tumor surveillance recommendations from the inaugural American Association for Cancer Research Childhood Cancer Predisposition Workshop, several other groups have proposed alternative consensus surveillance recommendations. Although these screening paradigms share some common elements, they also deviate from each other in some substantial ways. Clinical data continue to accrue in VHL, allowing the condition to be better characterized. Furthermore, surgical techniques have improved over time, and the option of targeted medical therapy has emerged for individuals with VHL. It is critical that surveillance strategies continue to be refined. In this perspective, we provide an up-to-date clinical overview of VHL, describe recently proposed tumor screening regimens, and finally present our updated consensus tumor surveillance recommendations during childhood and adolescence from the 2023 American Association for Cancer Research Childhood Cancer Predisposition Workshop.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-24-3525

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 48

  1. Maher, 2011, von Hippel-Lindau disease: a clinical and scientific review, Eur J Hum Genet, 19, 617, 10.1038/ejhg.2010.175 · DOI · Paper page
  2. Kaelin, 2017, The VHL tumor suppressor gene: insights into oxygen sensing and cancer, Trans Am Clin Climatol Assoc, 128, 298
  3. Maher, 1991, Von Hippel-Lindau disease: a genetic study, J Med Genet, 28, 443, 10.1136/jmg.28.7.443 · DOI · Paper page
  4. Binderup, 2022, von Hippel-Lindau disease: updated guideline for diagnosis and surveillance, Eur J Med Genet, 65, 104538, 10.1016/j.ejmg.2022.104538 · DOI · Paper page
  5. Launbjerg, 2017, von Hippel-Lindau development in children and adolescents, Am J Med Genet A, 173, 2381, 10.1002/ajmg.a.38324 · doi:10.1002/ajmg.a.38324
  6. Poulsen, 2010, Surveillance in von Hippel-Lindau disease (vHL), Clin Genet, 77, 49, 10.1111/j.1399-0004.2009.01281.x · doi:10.1111/j.1399-0004.2009.01281.x
  7. Maher, 1990, Clinical features and natural history of von Hippel-Lindau disease, Q J Med, 77, 1151, 10.1093/qjmed/77.2.1151 · DOI · Paper page
  8. Kreusel, 2005, Ophthalmological manifestations in VHL and NF 1: pathological and diagnostic implications, Fam Cancer, 4, 43, 10.1007/s10689-004-1327-0 · DOI
  9. Kreusel, 2006, Retinal angiomatosis in von Hippel-Lindau disease: a longitudinal ophthalmologic study, Ophthalmology, 113, 1418, 10.1016/j.ophtha.2006.02.059 · doi:10.1016/j.ophtha.2006.02.059
  10. Binderup, 2013, Von Hippel-Lindau disease (vHL). National clinical guideline for diagnosis and surveillance in Denmark. 3rd edition, Dan Med J, 60, B4763
  11. Binderup, 2018, von Hippel-Lindau disease: diagnosis and factors influencing disease outcome, Dan Med J, 65, B5461
  12. Nielsen, 2016, Von Hippel-Lindau disease: genetics and role of genetic counseling in a multiple neoplasia syndrome, J Clin Oncol, 34, 2172, 10.1200/JCO.2015.65.6140 · DOI · Paper page
  13. Daniels, 2023, Consensus guidelines for ocular surveillance of von Hippel-Lindau disease, Ophthalmology, 131, 622, 10.1016/j.ophtha.2023.12.014 · DOI · Paper page
  14. Huntoon, 2014, Findings from the natural history of central nervous system hemangioblastomas in von Hippel-Lindau disease, Neurosurgery, 61, N159, 10.1227/NEU.0000000000000384 · doi:10.1227/neu.0000000000000384
  15. Lonser, 2014, Prospective natural history study of central nervous system hemangioblastomas in von Hippel-Lindau disease, J Neurosurg, 120, 1055, 10.3171/2014.1.JNS131431 · DOI · Paper page
  16. Takayanagi, 2022, Hemangioblastoma and Von Hippel-Lindau disease, No Shinkei Geka, 50, 101
  17. Knoblauch, 2024, Screening and surveillance recommendations for central nervous system hemangioblastomas in pediatric patients with Von Hippel-Lindau disease, J Neurooncol, 168, 537, 10.1007/s11060-024-04676-5 · DOI · Paper page
  18. Li, 2020, Clinical and biochemical features of pheochromocytoma characteristic of Von Hippel-Lindau syndrome, World J Surg, 44, 570, 10.1007/s00268-019-05299-y · DOI
  19. Ashouri, 2015, Implications of Von Hippel-Lindau syndrome and renal cell carcinoma, J Kidney Cancer VHL, 2, 163, 10.15586/jkcvhl.2015.41 · DOI
  20. Kwon, 2014, Renal tumor size is an independent prognostic factor for overall survival in Von Hippel-Lindau disease, J Cancer Res Clin Oncol, 140, 1171, 10.1007/s00432-014-1654-y · doi:10.1007/s00432-014-1654-y
  21. Chahoud, 2021, Evaluation, diagnosis and surveillance of renal masses in the setting of VHL disease, World J Urol, 39, 2409, 10.1007/s00345-020-03441-3 · DOI
  22. O’Toole, 2018, Paediatric pancreatic neuroendocrine tumours in von Hippel-Lindau disease, Endocr Relat Cancer, 25, L43, 10.1530/ERC-18-0123 · doi:10.1530/erc-18-0123
  23. Zwolak, 2020, Pancreatic neuroendocrine tumours in patients with von Hippel-Lindau disease, Endokrynol Pol, 71, 256, 10.5603/EP.a2020.0027 · doi:10.5603/ep.a2020.0027
  24. Krauss, 2018, Preventive medicine of von Hippel-Lindau disease-associated pancreatic neuroendocrine tumors, Endocr Relat Cancer, 25, 783, 10.1530/ERC-18-0100 · DOI
  25. Bausch, 2016, Characterization of endolymphatic sac tumors and von Hippel-Lindau disease in the International Endolymphatic Sac Tumor Registry, Head Neck, 38, E673
  26. Mehta, 2022, Endolymphatic sac tumor screening and diagnosis in von Hippel-Lindau disease: a consensus statement, J Neurol Surg B Skull Base, 83, e225, 10.1055/s-0041-1725033 · doi:10.1055/s-0041-1725033
  27. Binderup, 2017, Survival and causes of death in patients with von Hippel-Lindau disease, J Med Genet, 54, 11, 10.1136/jmedgenet-2016-104058 · DOI · Paper page
  28. Prasad, 2011, Pediatric endocrine screening for von Hippel-Lindau disease: benefits and the challenge of compliance, J Endocrinol Invest, 34, 296, 10.1007/BF03347089 · DOI
  29. Priesemann, 2006, Benefits of screening in von Hippel-Lindau disease—comparison of morbidity associated with initial tumours in affected parents and children, Horm Res, 66, 1
  30. Jamshidi, 2024, Belzutifan in individuals with von Hippel-Lindau retinal hemangioblastomas: institutional experience and review of the literature, Ocul Oncol Pathol, 10, 154, 10.1159/000539434 · DOI
  31. Kuzbari, 2023, Germline-focused analysis of tumour-detected variants in 49,264 cancer patients: ESMO Precision Medicine Working Group recommendations, Ann Oncol, 34, 215, 10.1016/j.annonc.2022.12.003 · DOI
  32. Wolters, 2022, Multidisciplinary integrated care pathway for von Hippel-Lindau disease, Cancer, 128, 2871, 10.1002/cncr.34265 · DOI · Paper page
  33. Bratslavsky, 2021, Genetic risk assessment for hereditary renal cell carcinoma: clinical consensus statement, Cancer, 127, 3957, 10.1002/cncr.33679 · doi:10.1002/cncr.33679
  34. Reaume, 2013, Canadian guideline on genetic screening for hereditary renal cell cancers, Can Urol Assoc J, 7, 319, 10.5489/cuaj.1496 · doi:10.5489/cuaj.1496
  35. Koeller, 2022, An optimized protocol for evaluating pathogenicity of VHL germline variants in patients suspected with von Hippel-Lindau syndrome: using somatic genome to inform the role of germline variants, MethodsX, 9, 101761, 10.1016/j.mex.2022.101761 · DOI
  36. Rana, 2021, Pathogenicity of VHL variants in families with non-syndromic von Hippel-Lindau phenotypes: an integrated evaluation of germline and somatic genomic results, Eur J Med Genet, 64, 104359, 10.1016/j.ejmg.2021.104359 · DOI
  37. Zelley, 2024, Update on genetic counselor practice and recommendations for pediatric cancer predisposition evaluation and surveillance, Clin Cancer Res, 30, 3983, 10.1158/1078-0432.CCR-24-1165 · DOI
  38. Mougel, 2024, Update of the UMD-VHL database: classification of 164 challenging variants based on genotype-phenotype correlation among 605 entries, J Med Genet, 61, 378, 10.1136/jmg-2023-109550 · DOI
  39. Bento, 2018, Genetic basis of congenital erythrocytosis, Int J Lab Hematol, 40, 62, 10.1111/ijlh.12828 · DOI
  40. Rednam, 2017, Von Hippel-Lindau and hereditary pheochromocytoma/paraganglioma syndromes: clinical features, genetics, and surveillance recommendations in childhood, Clin Cancer Res, 23, e68, 10.1158/1078-0432.CCR-17-0547 · DOI · Paper page
  41. Daniels, 2023, Guidelines for surveillance of patients with von Hippel-Lindau disease: consensus statement of the International VHL Surveillance Guidelines Consortium and VHL Alliance, Cancer, 129, 2927, 10.1002/cncr.34896 · DOI · Paper page
  42. Johnson, 2012, Patterns of linear growth and skeletal maturation from birth to 18 years of age in overweight young adults, Int J Obes (Lond), 36, 535, 10.1038/ijo.2011.238 · doi:10.1038/ijo.2011.238
  43. Kruizinga, 2014, Calculating optimal surveillance for detection of von Hippel-Lindau-related manifestations, Endocr Relat Cancer, 21, 63, 10.1530/ERC-13-0308 · DOI
  44. Franscini, 2015, Pediatric reference intervals for plasma free and total metanephrines established with a parametric approach: relevance to the diagnosis of neuroblastoma, Pediatr Blood Cancer, 62, 587, 10.1002/pbc.25385 · DOI
  45. Peitzsch, 2019, Age-specific pediatric reference intervals for plasma free normetanephrine, metanephrine, 3-methoxytyramine and 3-O-methyldopa: particular importance for early infancy, Clin Chim Acta, 494, 100, 10.1016/j.cca.2019.03.1620 · DOI
  46. Zuo, 2018, High specificity of spot urinary free metanephrines in diagnosis and prognosis of pheochromocytomas and paragangliomas by HPLC with electrochemical detection, Clin Chim Acta, 478, 82, 10.1016/j.cca.2017.12.026 · DOI
  47. Sbardella, 2020, Random “spot” urinary metanephrines compared with 24-h-urinary and plasma results in phaeochromocytomas and paragangliomas, Eur J Endocrinol, 183, 129, 10.1530/EJE-19-0809 · DOI
  48. Boot, 2023, A laboratory medicine perspective on the investigation of phaeochromocytoma and paraganglioma, Diagnostics (Basel), 13, 2940, 10.3390/diagnostics13182940 · DOI

Metadata

Authors
Rednam, S. P., Becktell, K. D., Villani, A., Brodeur, G. M., States, L. J., Doria, A. S., Kamihara, J., Schneider, K. W., Voss, S. D., Widjaja, E., Zelley, K., Nakano, Y., Pajtler, K. W., Achatz, M. I., Malkin, D., Diller, L. R., Gallinger, B., Tamura, C., & Wasserman, J. D.
Venue
Clinical Cancer Research
Published
2025-04-15
Volume
31
Issue
12
Pages
2271-2277
ISSN
  • 1078-0432
  • 1557-3265
Cited by
17
References
3
Language
en
Funders
St. Baldrick’s Foundation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Update on Surveillance in Von Hippel–Lindau Disease. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-24-3525
The paper
Rednam, S. P., Becktell, K. D., Villani, A., Brodeur, G. M., States, L. J., Doria, A. S., Kamihara, J., Schneider, K. W., Voss, S. D., Widjaja, E., Zelley, K., Nakano, Y., Pajtler, K. W., Achatz, M. I., Malkin, D., Diller, L. R., Gallinger, B., Tamura, C., & Wasserman, J. D. (2025). Update on Surveillance in Von Hippel–Lindau Disease. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-24-3525

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.